Law.com Subscribers SAVE 30%

Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.

Medical Malpractice Law & StrategyLJN NewslettersNewsSections

Dilemma over Drug Safety

By Janice G. Inman
March 30, 2005

There is a newly urgent push from outside the pharmaceutical research and development community to get drug firms and the government to disclose the results of all tests conducted on new drugs and to immediately reveal information about problems that develop after those drugs go on the market. Consumers and health care providers say they're tired of finding out belatedly that negative information has come to light about the drugs they take or prescribe.

Of course, the Food and Drug Administration (FDA) has for years been looking out for the public by requiring extensive testing of all new drugs before they can be placed on the market, but critics charge that the agency, being intimately tied to the very industry it is policing, has not done enough. High on the list of concerns is the fact that after a drug is approved, its effects on consumers are not generally studied at present.

Consumer advocates have taken up the slack they see in the FDA's oversight of the drug manufacturing industry. For example, consumer group Public Citizen recently announced it had launched an updated Web site, www.WorstPills.org, to provide consumers with information about drugs the group considers unsafe or ineffective. The group, whose drug information Web site is accessible by subscription, claims that nearly 200 drugs on the market today are unsafe or ineffective.

This premium content is locked for Entertainment Law & Finance subscribers only

  • Stay current on the latest information, rulings, regulations, and trends
  • Includes practical, must-have information on copyrights, royalties, AI, and more
  • Tap into expert guidance from top entertainment lawyers and experts

For enterprise-wide or corporate acess, please contact Customer Service at [email protected] or 877-256-2473

Read These Next
Spurred By Data Breaches, CLOs Are Increasing Cybersecurity Leadership Role Image

Chief information officers still bear the brunt of cybersecurity worries at many companies. But a study by the Association of Corporate Counsel Foundation finds that chief legal officers are increasingly taking a leadership role in cybersecurity strategy.

GCs Want to Tap Into AI But Lack Roadmap, Report Shows Image

General counsel are eager to tap the promise of generative AI. But without clear technology road maps, many legal departments are struggling to turn that interest into action.

Is Google Search Dead? The Key to Thriving In an AI-Driven World Image

Part Two of this two-part articleexamines practical steps marketers must take to succeed in this changing landscape by embracing a multichannel, AI-driven approach to their marketing and PR efforts. This means rethinking your strategy to build direct connections with your audience, using platforms that elevate your visibility and focusing on storytelling that resonates.

Shifting Crypto and Cyber Enforcement Priorities In SEC Image

When the SEC issues the next annual enforcement report for fiscal year 2025, we expect securities offering actions and investment adviser actions will almost certainly be up, and the “crypto” and “cyber” cases will almost certainly be down. Public statements by the new SEC administration have said as much, but even more telling than public statements are the allocation of limited enforcement resources.

Seventh, Ninth Court Rulings Tighten Reach of Federal Video Privacy Protection Act Image

The VPPA may be nearly four-decades old and video-rental stores largely a thing of the past, but the rise of online content, streaming services and ancillary activities has brought with it frequent litigation based on the VPPA. The key challenge in these litigations is how to interpret the VPPA’s 1980s terms in light of today’s digital advances.